Evenamide for Negative Symptoms in Schizophrenia - Moves on to Phase 3 Clinical Trials

The oral selective glutamate inhibitor evenamide is moving on to advanced clinical trials on the strength of positive results in a phase 2 study, Ravi Anand, MD, reported at the annual congress of the European College of Neuropsychopharmacology.

Evenamide is a highly selective inhibitor of voltage-gated sodium channels that also attenuates glutamate release by hyperexcited neurons, explained Dr. Anand, chief medical officer at Newron Pharmaceuticals, a company based in Bresso, Italy, that is developing this novel antipsychotic agent.

The 4-week, randomized, double-blind, placebo-controlled, multicenter study included 89 patients with schizophrenia of a mean 18 years’ duration. All participants showed baseline evidence of breakthrough psychosis despite being on stable therapeutic doses of previously effective risperidone or aripiprazole. They were randomized either to add-on oral evenamide at a starting dose of 15 mg twice daily titrated to 20 or 25 mg twice daily or to placebo.

More info:


It’s an add-on to an existing AP not an AP in it’s own right from what I remember.

Yes, that’s right. From the previous studies the reduction in the PANSS was modest but broad, 75% of study patients received some benefit.

They said in a recent release though that it had the most effect in people under 32 with 10 or fewer years of illness.

They’re trying it for TRS as well, I don’t know / remember if it was going to be a standalone for that.

ETA here’s the other update from last month.

1 Like